BR112017010440A2 - administração sublingual de riluzol - Google Patents

administração sublingual de riluzol

Info

Publication number
BR112017010440A2
BR112017010440A2 BR112017010440A BR112017010440A BR112017010440A2 BR 112017010440 A2 BR112017010440 A2 BR 112017010440A2 BR 112017010440 A BR112017010440 A BR 112017010440A BR 112017010440 A BR112017010440 A BR 112017010440A BR 112017010440 A2 BR112017010440 A2 BR 112017010440A2
Authority
BR
Brazil
Prior art keywords
riluzole
sublingual administration
sublingual
sublingual formulation
administration
Prior art date
Application number
BR112017010440A
Other languages
English (en)
Inventor
M Berman Robert
Coric Vladimir
Original Assignee
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd filed Critical Biohaven Pharm Holding Co Ltd
Publication of BR112017010440A2 publication Critical patent/BR112017010440A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

a presente invenção refere-se à administração sublingual de riluzol. em particular, é fornecido um método para o tratamento de um transtorno ou sintoma neuropsiquiátrico por meio de administração de uma formulação sublingual de riluzol. além disso, é descrito um método para aliviar ou reduzir a dor oral usando a formulação sublingual de riluzol.
BR112017010440A 2014-11-21 2015-11-17 administração sublingual de riluzol BR112017010440A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083068P 2014-11-21 2014-11-21
PCT/US2015/061106 WO2016081466A1 (en) 2014-11-21 2015-11-17 Sublingual administration of riluzole

Publications (1)

Publication Number Publication Date
BR112017010440A2 true BR112017010440A2 (pt) 2017-12-26

Family

ID=55077617

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017010440A BR112017010440A2 (pt) 2014-11-21 2015-11-17 administração sublingual de riluzol

Country Status (14)

Country Link
US (1) US20180153862A1 (pt)
EP (1) EP3220890A1 (pt)
JP (1) JP2017535612A (pt)
KR (1) KR20170137030A (pt)
CN (1) CN107735077A (pt)
AU (1) AU2015350142A1 (pt)
BR (1) BR112017010440A2 (pt)
CA (1) CA2967659A1 (pt)
EA (1) EA201791110A1 (pt)
IL (1) IL252283A0 (pt)
MX (1) MX2017006454A (pt)
PH (1) PH12017500933A1 (pt)
SG (1) SG11201703897SA (pt)
WO (1) WO2016081466A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
JP2016534063A (ja) 2013-10-22 2016-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリン誘導体ならびに関連するイメージングおよび治療方法
CN107249567B (zh) 2014-11-21 2021-08-03 拜尔哈文制药股份有限公司 利鲁唑的舌下给药
US9899038B2 (en) 2016-06-30 2018-02-20 Karen Elaine Khaleghi Electronic notebook system
CN109922800B (zh) 2016-08-31 2023-06-13 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
RU2741577C2 (ru) * 2016-09-15 2021-01-27 Скинтек Лайф Сайенс Лимитед Сублингвальное или буккальное введение dim для лечения заболеваний кожи
BR112020016256A2 (pt) 2018-02-21 2020-12-15 AI Therapeutics, Inc. Terapia de combinação com apilimod e agentes gluta-matérgicos
US10235998B1 (en) 2018-02-28 2019-03-19 Karen Elaine Khaleghi Health monitoring system and appliance
WO2019199776A1 (en) * 2018-04-09 2019-10-17 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
AU2019277080A1 (en) * 2018-05-27 2021-01-07 Biohaven Pharmaceutical Holding Company Ltd. Use of riluzole oral disintigrating tablets for treating diseases
US20210315865A1 (en) * 2018-08-16 2021-10-14 Biohaven Therapeutics Ltd. Use of riluzole oral disintigrating tablets for treating diseases
US10559307B1 (en) 2019-02-13 2020-02-11 Karen Elaine Khaleghi Impaired operator detection and interlock apparatus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US5837287A (en) * 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
PT1187612E (pt) * 1999-06-04 2005-05-31 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Utilizacao do riluzole para o tratamento da esclerose multipla
AU2003226014A1 (en) * 2002-03-28 2003-10-13 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
JP2011093849A (ja) * 2009-10-30 2011-05-12 Kissei Pharmaceutical Co Ltd トラニラストの易溶性粉末吸入製剤
US9241933B2 (en) * 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
CN109316480A (zh) * 2011-07-13 2019-02-12 赛特凯恩蒂克公司 组合als疗法
IN2014DN07989A (pt) * 2012-03-01 2015-05-01 Pharnext

Also Published As

Publication number Publication date
EP3220890A1 (en) 2017-09-27
EA201791110A1 (ru) 2017-11-30
JP2017535612A (ja) 2017-11-30
WO2016081466A1 (en) 2016-05-26
US20180153862A1 (en) 2018-06-07
AU2015350142A1 (en) 2017-06-15
PH12017500933A1 (en) 2017-11-20
CN107735077A (zh) 2018-02-23
MX2017006454A (es) 2018-03-23
SG11201703897SA (en) 2017-06-29
KR20170137030A (ko) 2017-12-12
IL252283A0 (en) 2017-07-31
CA2967659A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
BR112017010440A2 (pt) administração sublingual de riluzol
BR112017010423A2 (pt) formulação sublingual de riluzol
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
EA201691582A1 (ru) Новые фармацевтические препараты
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
MY199091A (en) Therapeutic compounds
BR112016017317A8 (pt) composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
BR112017017729A2 (pt) forma de dosagem oral de liberação controlada de agonista de receptor gaba
EA201692278A1 (ru) Комбинации формотерола и будесонида для лечения хобл
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
CL2016000325A1 (es) Antagonistas de vía para tratar trastornos del sueño por cambio de fase
BR112017007138A2 (pt) composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto.
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
PH12016501483B1 (en) P-substituted asymmetric ureas and medical uses thereof
MX370436B (es) Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica.
BR112017009358A2 (pt) imunoterapia específica de peptídeo t terapêutico para uso no tratamento de metástase cerebral de um paciente com hla-2 positivo
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX2016005645A (es) Composicion farmaceutica topica de acitretina.
MX2016013451A (es) Heterociclilsulfonas arilo sustituidas.
BR112016016098A2 (pt) Compostos orgânicos
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements